Precipio (PRPO) Stock Analysis

What Precipio does

Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.

Key metrics

ETFs linked to PRPO

Broad-market and Healthcare sector ETFs an investor holding Precipio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PRPO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Precipio?

Precipio trades under the ticker PRPO on NASDAQ.

Which exchange is PRPO listed on?

PRPO is listed on NASDAQ.

What sector does Precipio operate in?

Precipio is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze PRPO in a portfolio?

PortView shows PRPO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.